ArticleMedicine2026
Potential protective function and causal association of LEPR in osteosarcoma: An integrated bioinformatics analysis and Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The highly heterogeneous properties and dynamic immunogenic features of osteosarcoma (OS) lead to limited therapeutic efficacy. The oncogenetic mechanisms of OS await further explanation, and new insights into therapeutic targets for OS remain urgent. We used single-cell RNA-sequencing data to identify cell type-specific differentially expressed genes between normal human osteocytes and OS cells. Subsequently, we analyzed the differential expression of leptin receptor (LEPR) in OS cell lines through in vitro experiments. We assessed the prognostic potential of LEPR and immune cell infiltration status associated with differential LEPR expression in OS patients. By integrating protein quantitative trait loci and methylation quantitative trait loci datasets with OS genome-wide association studies summary statistics, we performed Mendelian randomization analysis to elucidate the causal effect of LEPR on OS risk and identify cytosine-phosphate-guanine sites that may influence LEPR expression and OS risk. We observed lower LEPR expression in OS cell clusters compared to normal osteocyte clusters. RT-qPCR results indicated that the LEPR gene showed consistent differential expression in OS cells. Survival analysis revealed that lower LEPR expression was associated with worse survival outcomes in OS patients. OS patients with high LEPR expression tended to exhibit more immune cell infiltration. Mendelian randomization analysis indicated that genetically-determined LEPR was inversely associated with OS risk. We identified 8 methylation cytosine-phosphate-guanine sites within the LEPR promoter region causally associated with both lower LEPR protein expression and higher OS risk. Our integrated multi-omics analyses supported a causal association between LEPR expression and OS risk, suggesting that LEPR may offer protective benefits for OS patients. The relationship between LEPR and OS risk highlights the potential of LEPR as an early prognostic biomarker and may provide new insights into the etiology of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.